Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-arm Multi-center Study of Ruxolitinib in Chinese Participants With Corticosteroid-refractory Chronic Graft Versus Host Disease After Allogeneic Stem Cell Transplantation

NCT06824103 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.

NCT NCT06824103
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06824103 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-arm Multi-center Study of Ruxolitinib in Chinese Participants With Corticosteroid-refractory Chronic Graft Versus Host Disease After Allogeneic Stem Cell Transplantation
Lead sponsor
Novartis Pharmaceuticals
Phase
Phase 4
Overall status
Recruiting
Start date
September 9, 2025
Completion date
May 23, 2031
Enrollment
50 (estimated)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

chronic graft vs. host disease, corticosteroid-refractory chronic graft vs. host disease, graft vs. host disease